Conditions: Ovarian Cancer
Keywords: ovarian cancer recurrent Gleevec Paclitaxel Taxane mullerian
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 14
Healthy volunteers: no

Brief summary:
This study is designed to determine whether the combination treatment of Paclitaxel and Gleevec on recurrent ovarian cancer patients or other cancers of mullerian origin will generate better clinical response than Paclitaxel alone.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Gleevec/Paclitaxel
Intervention descriptions: intervention 1: One treatment cycle:

Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.

Paclitaxel: 80 mg/m\^2/week intravenously, 3 weeks on, one week off, every 28 days.

After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression.

Protocol document: